rethinkTHC Search
Menu
Study breakdown

Brain Imaging Finds CB1 Receptor Levels Linked to Emotional Numbing in PTSD, Not Overall Diagnosis

PET Imaging StudyModerate evidence
The takeaway

A PET study found no overall difference in CB1 receptor availability between PTSD patients and controls, but emotional numbing symptoms were significantly linked to CB1 receptor levels, suggesting a nuanced endocannabinoid role.

PTSD researchers, psychiatrists, endocannabinoid system researchers

CB1R linked to emotional numbing, not PTSD diagnosis overall

What the researchers found

Among 62 participants (19 with current PTSD, 27 trauma-exposed controls, 16 healthy controls), no differences in CB1 receptor availability were found between groups in whole brain or regions of interest. However, emotional numbing symptoms of PTSD were significantly associated with CB1R availability, suggesting the endocannabinoid system relates to specific symptom dimensions rather than the diagnosis overall.

Why it matters

This challenges a previous study that found elevated CB1R in PTSD and refines our understanding. The endocannabinoid system may not drive PTSD broadly but could specifically contribute to emotional numbing, which is one of the most treatment-resistant symptom clusters.

The numbers in context

62 participants; 19 with PTSD; no group differences in CB1R availability; significant association between CB1R and emotional numbing symptoms specifically.

How the study worked

PET imaging study using [11C]OMAR, a CB1R-specific radiotracer, in 62 individuals. 46 trauma-exposed (19 with current PTSD) and 16 healthy controls. Analysis of whole-brain and region-of-interest CB1R availability correlated with PTSD symptom clusters.

What this study cannot tell us

Modest sample size (19 PTSD patients). Cross-sectional design. Single PET tracer. Cannabis use history in participants could affect CB1R availability. Cannot determine directionality of the CB1R-numbing association.

How to read the evidence

PET imaging with specific radiotracer provides direct receptor measurement, but modest sample size and cross-sectional design limit conclusions.

When this study was published

2025 publication

The bigger picture

The finding that CB1R relates to emotional numbing specifically could explain why some PTSD patients report cannabis helps "feel again" while others find it worsens dissociation. It supports developing cannabinoid-targeted treatments for specific PTSD symptom clusters rather than PTSD as a whole.

Questions still open

  • Would cannabinoid therapies specifically targeting emotional numbing be more effective than broad PTSD treatments?
  • Do CB1R levels change with PTSD treatment or symptom improvement?

Common questions

Is the endocannabinoid system involved in PTSD?
This PET study found no overall difference in CB1 receptor levels between PTSD patients and controls. However, CB1R was specifically linked to emotional numbing symptoms, suggesting the endocannabinoid system plays a nuanced role in specific PTSD symptom dimensions.
Can cannabis help with PTSD numbing?
This study found a biological link between CB1 receptor levels and emotional numbing in PTSD. While this provides a rationale for cannabinoid-targeted treatments, clinical trials are needed to determine whether modulating CB1R actually improves numbing symptoms.

Read the original research

Cannabinoid 1 receptor availability in posttraumatic stress disorder: A positron emission tomography study.

Translational psychiatry, 15(1), 310

Citation

Korem, Nachshon; Bassir Nia, Anahita; Hillmer, Ansel T; D'Souza, Deepak; Nabulsi, Nabeel; Ropchan, Jim; Huang, Yiyun; Cosgrove, Kelly; Levy, Ifat; Pietrzak, Robert H; Harpaz-Rotem, Ilan. (2025). Cannabinoid 1 receptor availability in posttraumatic stress disorder: A positron emission tomography study.. Translational psychiatry, 15(1), 310. https://doi.org/10.1038/s41398-025-03519-9

Explore the wider topic